<DOC>
	<DOC>NCT02488421</DOC>
	<brief_summary>The purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and VKAs in patients with NVAF.</brief_summary>
	<brief_title>Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2</brief_title>
	<detailed_description>Actual number of patients enrolled for UK : 15242 patients Actual number of patients enrolled for Germany : 22880 patients</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Have an apixaban, rivaroxaban, dabigatran or VKA prescription during the study period Are ≥18 years old at index date Have ≥12 months of computerised medical data prior to index date Have a record of AF on or ever prior to index date (index OAC prescription) Have a record for a valvular condition (ie, rheumatic valvular disease and prosthetic valves) on or ever prior to index date Have a history (ever prior to index date) of the Oral anticoagulant (OACs) which are prescribed during the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>